Observational analysis explores elabela's potential in targeted treatment of acute myeloid leukaemia, suggesting reduced side effects.
Acute myeloid leukaemia is a clonal stem cell disease. Various molecular targets are being sought in this disease which has a low chance of cure. However, it is desired that targeted treatments should have few side effects. We tried to understand whether the embryogenic peptide elabela, which has been closely associated with many pathways involved in cancer mechanism, is a peptide worth investigating in targeted treatment of acute myeloid leukaemia.
No takes yet. Share an insight, caveat, or question.
Açık et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: